ACHL Achilles Therapeutics PLC

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics (ACHL - Research Report) today and set a price target of $20.00. The company's shares closed yesterday at $1.79.Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Solid Biosciences. According to TipRanks, Livshits has an average return of 24.8% and a 40.24% success rate on recommended stocks. Achilles Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.See the top stocks recommended by analysts >>The company has a one-year high of $6.88 and a one-year low of $1.72. Currently, Achilles Therapeutics has an average volume of 26.92K.
https://www.tipranks.com/news/blurbs/chardan-capital-keeps-their-buy-rating-on-achilles-therapeutics-achl?utm_source=advfn.com&utm_medium=referral